Wall Street isn't convinced the Ozempic maker has a promising path back to sustainable growth as competition from Eli Lilly intensifies.
Source: [CNBC](https://www.cnbc.com/2026/08/05/novo-nordisk-stock-guidance-earnings-wegovy-ozempic-eli-lilly.html)